Wednesday, 11 April 2012

Complete Response-Glaxosmithkline-Public Citizen-Preterm Birth-Fda Committee

Latest News From 'The Pink Sheet' DAILY - Watson Gets Complete Response Letter For Its Progesterone Gel

Merck KGaA plans to cut staff and costs - GlaxoSmithKline pays $31.5 million upfront to access Angiochem's rare disease technologies - Public Citizen details $106 million in device lobbying as cause for concern - Watson receives complete response letter for progesterone gel to reduce preterm birth - FDA committee review of Replagal will include closed door session on manufacturing - FDA panel assesses risk of using anti-inflammatory eyedrops for both eyes - Teva to initiate a third clinical trial of multiple sclerosis drug laquinimod - FDA consider new paradigm to facilitate third class of drugs - Takeda's TAK-875 early data suggests the compound could take on other oral antidiabetics read more..

No comments:

Post a Comment